Clinical Trial Update: Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update from Teva investigating HPA axis safety in adults and adolescents with perennial allergic rhinitis, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Perennial Allergic Rhinitis | Phase 3 | Status: COMPLETED | Results posted: 2012-07-04